China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Double Crane Runchuang received approval from China's drug administrator to conduct clinical trials for DC50292A.
DC50292A tablets are intended to be used to treat patients with advanced solid tumors, according to a Monday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.